French Pharma Stock News

Key Insights Significant control over Neurones by private companies implies that the general public has more power to...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

ENENSYS Technologies SA ( EPA:ALNN6 ) shareholders would be excited to see that the share price has had a great month...

Safran recently saw a 300%+ jump in trading volume as investors reacted to its positioning in a recovering aerospace and defense market and looked ahead to its February 2026 earnings announcement. This surge in activity highlights how expectations around Safran’s focus on aircraft interiors, avionics and propulsion systems are shaping investor interest in the sector. We’ll now examine how this renewed trading interest, tied to Safran’s aerospace rebound exposure, interacts with and...

BNP Paribas (ENXTPA:BNP) has been quietly grinding higher this year, and with the stock up about 35 % year-to-date, it is a good moment to revisit what is actually driving that strength. See our latest analysis for BNP Paribas. That move has not come out of nowhere, with a 13.9% 1 month share price return building on steady execution and solid earnings that have pushed the 1 year total shareholder return to roughly 54%, signalling momentum that still looks constructive rather than...

Sanofi (ENXTPA:SAN) shares have quietly bounced about 2% over the past week, even though they are still down for the year, drawing attention from investors looking for more resilient pharma exposure. See our latest analysis for Sanofi. That recent 7 day share price return of 2.21 percent only slightly offsets a year to date share price decline of 12.66 percent. This suggests sentiment is stabilising rather than surging, despite steady earnings growth and pipeline progress. If Sanofi has you...

BASSAC Société anonyme's ( EPA:BASS ) price-to-earnings (or "P/E") ratio of 8.7x might make it look like a buy right...

Kering (ENXTPA:KER) has quietly climbed this year, and with the share price hovering around €303 after a recent pullback, investors are starting to reassess whether the luxury group’s recovery has more room to run. See our latest analysis for Kering. The recent pullback sits against a strong backdrop, with a roughly 28 percent year to date share price return. This suggests sentiment toward Kering’s turnaround is improving even as the three and five year total shareholder returns remain deeply...

Nexans S.A. ( EPA:NEX ), might not be a large cap stock, but it received a lot of attention from a substantial price...

Key Insights Given the large stake in the stock by institutions, Alten's stock price might be vulnerable to their...

Veolia Environnement SA ( EPA:VIE ) saw its share price hover around a small range of €28.40 to €29.97 over the last...

If you are wondering whether Sanofi is quietly turning into a bargain while everyone is focused on flashier names, this deep dive will help you assess whether the current price reflects its long term potential. Despite a solid 5 year gain of 28.1%, the stock is down 12.7% year to date and 4.6% over the last month, suggesting that sentiment has cooled even as the long term story remains intact. Recently, markets have been reacting to Sanofi's strategic shifts in its pharmaceutical pipeline...

If you are wondering whether LVMH Moët Hennessy Louis Vuitton Société Européenne is still a quality luxury name at a fair price, you are not alone. That is exactly what we are going to unpack here. The share price has been relatively steady but slightly positive, up around 1.2% over the last week and 3.6% over the past month, while sitting roughly flat year to date and modestly higher over 1 year. This hints at cautious optimism rather than a runaway rally. Recent headlines have focused on...

Wondering if Publicis Groupe is quietly turning into a value opportunity, or if the market has already priced in the upside? The stock has edged up about 1.5% over the last week and 5.5% over the past month, even though it is still down roughly 13.9% year to date and 10.2% over the last year after a very strong 3 and 5 year run. Recent headlines have focused on Publicis tightening its focus on high margin data and tech led services and securing new global client mandates, reinforcing its...

In July 2025, Laura Burdese took over as CEO of Bulgari, succeeding long-time leader Jean-Christophe Babin, who remains chairman and head of the Bulgari Hotel business unit. This leadership reshuffle at one of LVMH’s key jewelry and hospitality brands could subtly reshape how the group balances heritage with expansion. We’ll now explore how Burdese’s appointment at Bulgari might influence LVMH’s broader investment narrative, especially around brand diversification and luxury hospitality. The...

If you are wondering whether Atos at around €46 is a turnaround bargain or a value trap, you are not the only one. That is exactly what this breakdown is going to tackle. The stock has swung hard lately, down 15.9% over the last week but still up 6.0% over 30 days, with an eye catching 85.8% gain year to date and a 121.2% rise over the past year after a brutal multi year slide. Those moves come after years of restructuring and strategic shifts that have investors rethinking the long term...

Sanofi halted development of tolebrutinib in primary progressive multiple sclerosis after the drug missed its Phase 3 primary endpoint. The company signed a licensing deal worth up to $1.04 billion with ADEL for an investigational Alzheimer’s antibody. Sanofi expanded its collaboration with Dren Bio to advance next generation B cell targeted therapies for autoimmune diseases. Regulatory progress includes approvals for new rare disease medicines in China and EMA orphan designation for an...

Thales (ENXTPA:HO) just rolled out its AI Security Fabric, a platform aimed at shielding Agentic AI and LLM apps from threats like prompt injection and data leakage, and the stock is starting to reflect that shift. See our latest analysis for Thales. That launch lands after a strong run, with the latest share price at €231.2 and a year to date share price return of 68.02 percent. The five year total shareholder return of 241.04 percent shows longer term momentum has been firmly building...

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

Gaztransport & Technigaz (ENXTPA:GTT) has caught investors attention after naming François Michel as its next CEO, effective January 2026. The move restores split governance and sharpens focus on technology driven growth. See our latest analysis for Gaztransport & Technigaz. The appointment of François Michel comes after a choppy stretch, with a 1 month share price return of minus 13.0% even as the year to date share price return is still up 15.2% and the 1 year total shareholder return of...

On 5 December 2025, Dynamatic Technologies Limited announced an expanded agreement with Dassault Aviation to manufacture and assemble the complete rear fuselage (Section 5) of the Falcon 6X, building on its earlier work industrialising the rear fuel tank already in commercial production. This deeper manufacturing role not only strengthens Dassault Aviation’s supply chain for the Falcon 6X, but also broadens its industrial footprint in India under the Make in India policy, potentially...

SPIE (ENXTPA:SPIE) just deepened its relationship with Tesla through a multi year European framework agreement for battery energy storage projects, a strategic move that plugs SPIE directly into the grid scale transition story. See our latest analysis for SPIE. Those moves sit against a strong backdrop, with the share price up sharply this year on the back of the Tesla framework, energy transition acquisitions and an upcoming anti dilutive buyback, signalling building momentum and improving...

If you are wondering whether Engie is still good value after such a strong run, or if you are turning up late to the party, this breakdown will help you decide whether the current price still makes sense. Engie’s share price has barely moved over the last week (up 0.4%) and month (down 0.3%). However, those quiet short term moves sit on top of a 40.0% gain year to date and a 58.6% rise over the past year, with returns of 110.9% over 3 years and 158.8% over 5 years. Part of this strength...

Sanofi recently reported that its PERSEUS Phase 3 trial found the multiple sclerosis drug tolebrutinib failed to delay disability progression in primary progressive MS, leading the company to stop seeking approval for this indication while the FDA review for non‑relapsing secondary progressive MS is pushed beyond the previously expected December 2025 decision date. At the same time, Sanofi has expanded its presence in rare blood disorders in China with approvals for Qfitlia in hemophilia and...